BJH - volume 10, issue 3, may 2019
M.C. Vekemans MD, N. Meuleman MD, PhD, C. Doyen MD, PhD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, L. Michaux MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory agents and proteasome inhibitors, major improvements have been achieved in the treatment and outcome of multiple myeloma. Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation remains the corner stone of therapy for fit, newly-diagnosed multiple myeloma patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.
(BELG J HEMATOL 2019;10(3):113–21)
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M.C. Vekemans MD, N. Meuleman MD, PhD, C. Doyen MD, PhD, K.L. Wu MD, PhD, P. Mineur MD, G. Bries MD, PhD, A. Kentos MD, L. Michaux MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and newer therapies are being developed. Nevertheless, autologous stem cell transplantation (ASCT) remains the corner stone of therapy for fit, newly-diagnosed MM patients. Based on an extensive review of the recent literature, we propose recommendations on myeloma care, to be used by haematologists as a reference for daily practice.
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
C. Doyen MD, PhD, M.C. Vekemans MD
Multiple Myeloma (MM) is mainly a disease of the elderly. In 2018 bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) are the established standard of care first-line regimens. Before starting therapy, an accurate evaluation of the frailty of patients is needed which allows physicians to individualize the approach for the individual patient.
Read moreBJH - volume 9, issue 1, february 2018
M.C. Vekemans MD
With more than 900 abstracts focusing on multiple myeloma (MM), the 2017 annual meeting of the American Society of Hematology (ASH) shows once more the great interest of the myeloma community in identifying new potential targets and developing novel therapeutic strategies for this devastating disease.
(BELG J HEMATOL 2018;9(1):8–11)
Read more
Top
